181 related articles for article (PubMed ID: 37737952)
1. Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.
Xue Y; Hu J; Liu D; Li J; Wu H; Tan C; Dai L; Sun L; Li Z; Xiao Z; Huang C; Yan Y; Ji F; Chen R; Zou H
BioDrugs; 2024 Jan; 38(1):145-156. PubMed ID: 37737952
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.
Deodhar A; Poddubnyy D; Pacheco-Tena C; Salvarani C; Lespessailles E; Rahman P; Järvinen P; Sanchez-Burson J; Gaffney K; Lee EB; Krishnan E; Santisteban S; Li X; Zhao F; Carlier H; Reveille JD;
Arthritis Rheumatol; 2019 Apr; 71(4):599-611. PubMed ID: 30343531
[TBL] [Abstract][Full Text] [Related]
3. Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging.
Maksymowych WP; Bolce R; Gallo G; Seem E; Geneus VJ; Sandoval DM; Østergaard M; Tada K; Baraliakos X; Deodhar A; Gensler LS
Rheumatology (Oxford); 2022 Nov; 61(11):4324-4334. PubMed ID: 35188180
[TBL] [Abstract][Full Text] [Related]
4. Rapid and Sustained Effect of Ixekizumab on Patient Global, Spinal Pain, Stiffness, and Fatigue in Chinese Patients with Radiographic Axial Spondyloarthritis.
Zhu X; Hu J; Liu D; Li J; Wu H; Sun L; Dai L; Tan C; Li Z; Xiao Z; Li X; Yan Y; Dou G; Sun Y; Zou H
Rheumatol Ther; 2024 Jun; ():. PubMed ID: 38907104
[TBL] [Abstract][Full Text] [Related]
5. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde D; Cheng-Chung Wei J; Dougados M; Mease P; Deodhar A; Maksymowych WP; Van den Bosch F; Sieper J; Tomita T; Landewé R; Zhao F; Krishnan E; Adams DH; Pangallo B; Carlier H;
Lancet; 2018 Dec; 392(10163):2441-2451. PubMed ID: 30360964
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
Dougados M; Wei JC; Landewé R; Sieper J; Baraliakos X; Van den Bosch F; Maksymowych WP; Ermann J; Walsh JA; Tomita T; Deodhar A; van der Heijde D; Li X; Zhao F; Bertram CC; Gallo G; Carlier H; Gensler LS;
Ann Rheum Dis; 2020 Feb; 79(2):176-185. PubMed ID: 31685553
[TBL] [Abstract][Full Text] [Related]
7. Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials.
van der Horst-Bruinsma IE; de Vlam K; Walsh JA; Bolce R; Hunter T; Sandoval D; Zhu D; Geneus V; Soriano ER; Magrey M
Adv Ther; 2022 Jun; 39(6):2806-2819. PubMed ID: 35429281
[TBL] [Abstract][Full Text] [Related]
8. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
Deodhar A; van der Heijde D; Gensler LS; Kim TH; Maksymowych WP; Østergaard M; Poddubnyy D; Marzo-Ortega H; Bessette L; Tomita T; Leung A; Hojnik M; Gallo G; Li X; Adams D; Carlier H; Sieper J;
Lancet; 2020 Jan; 395(10217):53-64. PubMed ID: 31813637
[TBL] [Abstract][Full Text] [Related]
9. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Mease PJ; van der Heijde D; Ritchlin CT; Okada M; Cuchacovich RS; Shuler CL; Lin CY; Braun DK; Lee CH; Gladman DD;
Ann Rheum Dis; 2017 Jan; 76(1):79-87. PubMed ID: 27553214
[TBL] [Abstract][Full Text] [Related]
10. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
Chandran V; van der Heijde D; Fleischmann RM; Lespessailles E; Helliwell PS; Kameda H; Burgos-Vargas R; Erickson JS; Rathmann SS; Sprabery AT; Birt JA; Shuler CL; Gallo G
Rheumatology (Oxford); 2020 Oct; 59(10):2774-2784. PubMed ID: 32031665
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
van der Heijde D; Gladman DD; Kishimoto M; Okada M; Rathmann SS; Moriarty SR; Shuler CL; Carlier H; Benichou O; Mease PJ
J Rheumatol; 2018 Mar; 45(3):367-377. PubMed ID: 29247148
[TBL] [Abstract][Full Text] [Related]
12. Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies.
Kiltz U; Wei JC; van der Heijde D; van den Bosch F; Walsh JA; Boonen A; Gensler LS; Hunter T; Carlier H; Dong Y; Li X; Bolce R; Strand V; Braun J
J Rheumatol; 2021 Feb; 48(2):188-197. PubMed ID: 32669450
[TBL] [Abstract][Full Text] [Related]
13. Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results.
Deodhar AA; Mease PJ; Rahman P; Navarro-Compán V; Strand V; Hunter T; Bolce R; Leon L; Lauzon S; Marzo-Ortega H
BMC Rheumatol; 2021 Sep; 5(1):35. PubMed ID: 34538257
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST.
Braun J; Kiltz U; Deodhar A; Tomita T; Dougados M; Bolce R; Sandoval D; Lin CY; Walsh J
RMD Open; 2022 Jul; 8(2):. PubMed ID: 35853675
[TBL] [Abstract][Full Text] [Related]
15. Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis.
Maksymowych WP; Baraliakos X; Lambert RG; Landewé R; Sandoval D; Carlier H; Lisse J; Li X; Hojnik M; Østergaard M
Lancet Rheumatol; 2022 Sep; 4(9):e626-e634. PubMed ID: 38288892
[TBL] [Abstract][Full Text] [Related]
16. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).
Gottlieb AB; Strand V; Kishimoto M; Mease P; Thaçi D; Birt J; Lee CH; Shuler CL; Lin CY; Gladman DD
Rheumatology (Oxford); 2018 Oct; 57(10):1777-1788. PubMed ID: 29945203
[TBL] [Abstract][Full Text] [Related]
17. Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate.
Poddubnyy D; Hammel L; Heyne M; Veit J; Jentzsch C; Baraliakos X
BMJ Open; 2020 Sep; 10(9):e039059. PubMed ID: 32998926
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
19. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Deodhar A; Van den Bosch F; Poddubnyy D; Maksymowych WP; van der Heijde D; Kim TH; Kishimoto M; Blanco R; Duan Y; Li Y; Pangan AL; Wung P; Song IH
Lancet; 2022 Jul; 400(10349):369-379. PubMed ID: 35908570
[TBL] [Abstract][Full Text] [Related]
20. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
